{"filing":{"accession_number":"0001628280-26-051051","cik":"0001855175","ticker":"CTNM","company_name":"Contineum Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"ctnm-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/ctnm-20260730.htm"},"events":[{"id":22685,"run_id":20522,"accession_number":"0001628280-26-051051","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses Contineum Therapeutics' second-quarter 2026 financial results via a press release issued on July 30, 2026, including condensed statements of operations and balance sheets. The press release reports Q2 2026 net loss of $15.2 million, R\u0026D expenses of $12.7 million, cash position of $236.6 million, and affirms key clinical development milestones for PIPE-791 and PIPE-307. This is a standard earnings release disclosure under Item 2.02.","company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22701,"accession_number":"0001628280-26-051051","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Contineum Therapeutics' second-quarter 2026 financial results via a press release issued on July 30, 2026, including condensed statements of operations and balance sheets. The press release reports Q2 2026 net loss of $15.2 million, R\u0026D expenses of $12.7 million, cash position of $236.6 million, and affirms key clinical development milestones for PIPE-791 and PIPE-307. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:17:46.652402+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22701,"accession_number":"0001628280-26-051051","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Contineum Therapeutics' second-quarter 2026 financial results via a press release issued on July 30, 2026, including condensed statements of operations and balance sheets. The press release reports Q2 2026 net loss of $15.2 million, R\u0026D expenses of $12.7 million, cash position of $236.6 million, and affirms key clinical development milestones for PIPE-791 and PIPE-307. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:17:46.652402+00:00","company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","filing_date":"2026-07-30"}]}